Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients.

@article{Ferguson2003ReboxetineVP,
  title={Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients.},
  author={J. Mitchell Ferguson and Keith A Wesnes and Gerri E Schwartz},
  journal={International clinical psychopharmacology},
  year={2003},
  volume={18 1},
  pages={9-14}
}
Impaired cognitive functioning is often associated with major depressive disorder (MDD). Moreover, a number of agents used to treat MDD are known to have negative effects on cognitive functioning. We report an assessment of the effects of the selective norepinephrine reuptake inhibitor reboxetine, the selective serotonin reuptake inhibitor paroxetine, and placebo on a variety of measures of cognitive functioning in patients with MDD. Cognitive functioning in 74 adult patients (aged 18-65 years… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

Acute and Chronic Noradrenergic Effects on Cortical Excitability in Healthy Humans

The international journal of neuropsychopharmacology • 2017
View 3 Excerpts

Similar Papers

Loading similar papers…